Table 2.
Overview of ongoing clinical trials in which promising predictive and prognostic liquid biopsy-based biomarkers are investigated in NSCLC patients. Ongoing clinical trials were found at the website of https://www.Clinicaltrials.gov (accessed on 27 November 2020). An advanced search was performed with the words: “(NSCLC OR non-small cell lung cancer) AND (immunotherapy OR PD-L1 or PD-1) in combination with: (cfDNA OR cell-free DNA); (CTC or circulating tumor cell); exosomes; epigenetics; miRNA; (T cell repertoire OR TCR); gut microbiota or (eNose OR breath)”. Results of the completed trials are available, the other trials have not provided their study results on ClinicalTrials.gov yet. BC: breast cancer; CRC: colorectal cancer; H&NC: head and neck cancer; KC: kidney cancer; MC: melanoma cancer; NSCLC: non-small cell lung cancer; PC: pancreas cancer; RC: renal cancer; UC: urothelial carcinoma.
| Trial | Cancer Type | Therapy | # Patients | Markers | End Date |
|---|---|---|---|---|---|
| NCT02511288 | NSCLC | Immunotherapy, targeted therapy | 900 | cfDNA, miRNA | 2026 |
| NCT04107168 | MC, NSCLC, RC | Immunotherapy | 1.800 | microbiome | 2025 |
| NCT04146064 | H&NC, KC, MC, NSCLC, UC | Immunotherapy | 425 | eNose | 2024 |
| NCT04638751 | BC, CRC, NSCLC, PC | Chemotherapy, immunotherapy | 4.000 | microbiome | 2024 |
| NCT03926260 | NSCLC | Chemotherapy, immunotherapy, targeted therapy | 100 | cfDNA | 2023 |
| NCT04629027 | NSCLC | Immunotherapy | 80 | CTC, TCR | 2023 |
| NCT04636047 | NSCLC | Immunotherapy | 450 | cfDNA (bTMB), TCR | 2023 |
| NCT04636775 | NSCLC | Immunotherapy | 46 | microbiome | 2022 |
| NCT04427475 | NSCLC | Immunotherapy | 900 | cfDNA, miRNA | 2022 |
| NCT03512847 | NSCLC | Chemotherapy, immunotherapy | 150 | cfDNA | 2021 |
| NCT03481101 | NSCLC | Chemotherapy, immunotherapy | 60 | cfDNA | 2021 |
| NCT04291755 | CRC, NSCLC | Immunotherapy | 100 | microbiome | 2021 |
| NCT03178552 | NSCLC | Immunotherapy, targeted therapy | 660 | cfDNA (bTMB) | 2021 |
| NCT02827344 | NSCLC | Immunotherapy | 200 | CTC | 2021 |
| NCT03892096 | BC, CRC, NSCLC | Chemotherapy, immunotherapy, targeted therapy | 750 | cfDNA | 2021 |
| NCT03576937 | NSCLC | Chemotherapy, immunotherapy, targeted therapy | 210 | cfDNA | 2020 |
| NCT03986463 | NSCLC | Chemotherapy, radiotherapy | 30 | cfDNA | 2020 |
| NCT03373955 | NSCLC | Chemotherapy, immunotherapy, targeted therapy | 60 | cfDNA, TCR | 2020 |
| NCT02551211 | NSCLC | Immunotherapy | 58 | cfDNA, TCR | 2019 |
| NCT02890849 | NSCLC | Immunotherapy, radiotherapy | 60 | Exosomes, mRNA | 2019 |
| NCT01903993 | NSCLC | Chemotherapy, immunotherapy | 287 | cfDNA (bTMB) | Completed |
| NCT02008227 | NSCLC | Chemotherapy, immunotherapy | 1.225 | cfDNA (bTMB) | Completed |